HDAC6 interacts with PTPN1 to enhance melanoma cells progression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HDAC6 interacts with PTPN1 to enhance melanoma cells progression

Published:2018-01 Issue:4 Volume:495 Page:2630-2636
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Liu Jiaqi,Luan Wenjie,Zhang Yong,Gu Jianying,Shi Yuedong,Yang Yanwen,Feng Zihao,Qi Fazhi

Funder

National Natural Science Foundation of China

National Key R&D Project

Zhongshan Hospital

Research & Development Grant of Zhongshan Hospital

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference35 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin.,2015

2. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat. Rev. Clin. Oncol.,2017

3. MiR-211 is epigenetically regulated by DNMT1 mediated methylation and inhibits EMT of melanoma cells by targeting RAB22A;Yu;Biochem. Biophys. Res. Commun.,2016

4. Melanoma growth and lymph node metastasis is independent of host CD169 expression;Muhsin-Sharafaldine;Biochem. Biophys. Res. Commun.,2017

5. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma;Sun;Nature,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetics and Control of Tumor Angiogenesis in Melanoma: An Update with Therapeutic Implications;Cancers;2024-08-14

2. Histone deacetylase (HDACs) inhibitors: Clinical applications;Epigenetics in Health and Disease - Part B;2023

3. Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template;Bioorganic & Medicinal Chemistry;2022-11

4. The emerging roles of HDACs and their therapeutic implications in cancer;European Journal of Pharmacology;2022-09

5. HDAC6: A unique HDAC family member as a cancer target;Cellular Oncology;2022-08-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3